VJHemOnc is committed to improving our service to you

SOHO Italy 2020 | Balancing efficacy and tolerability in multiple myeloma

VJHemOnc is committed to improving our service to you

Patrizia Tosi

Patrizia Tosi, MD, Infermi Hospital, Rimini, Italy, discusses the importance of balancing efficacy and toxicity in the era of novel agents in the treatment of multiple myeloma. Dr Tosi also discusses side effects associated with monoclonal antibodies and cellular therapies such as hematological toxicities as well as highlighting belantamab mafodotin, a efficacious antibody-drug conjugate in multiple myeloma with corneal side effects. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter